The Effect of Oral Alpha-Cyclodextrin on Fecal Fat Excretion

Withdrawn before enrolling · Not applicable

Conditions studied: Obesity, Cardiovascular Disease

In brief

Saturated fat leading to elevated low density lipoprotein (LDL) cholesterol is considered a cardiovascular risk factor. The properties associated with α- cyclodextrin, allow it to selectively reduce saturated fat and calories which will have a medically beneficial effect on LDL cholesterol and obesity. The purpose of the research is to evaluate this effect of α- cyclodextrin. It is hypothesized that alpha cyclodextrin supplementation will increase fecal fat on a high saturated fat diet compared to the same diet supplemented with a digestible carbohydrate control

Key facts

Study ID

NCT01910558

Run by

Pennington Biomedical Research Center

People needed

0

Starts

2013-10-01

Expected to finish

2013-10-01

Last updated by the study team

2016-04-27

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• BMI between 20 and 30 kg/m2 inclusive
• Weight ≥ 65 kg for females, and ≥ 55 kg for males

You may not qualify if…

• Pregnant or nursing.
• Diabetes Mellitus
• Any medication to reduce lipids
• History of gastrointestinal surgery, except for cholecystectomy or appendectomy
• History of malabsorption

Where it is running

• Pennington Biomedical Research Center — Baton Rouge, Louisiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.